Heart Transplantation from COVID-19-Positive Donors: A Word of Caution

Transplant Proc. 2023 Apr;55(3):533-539. doi: 10.1016/j.transproceed.2023.02.048. Epub 2023 Mar 3.

Abstract

Background: During the COVID-19 pandemic, efforts to maintain solid-organ transplantation have continued, including the use of SARS-CoV-2-positive heart donors.

Methods: We present our institution's initial experience with SARS-CoV-2-positive heart donors. All donors met our institution's Transplant Center criteria, including a negative bronchoalveolar lavage polymerase chain reaction result. All but 1 patient received postexposure prophylaxis with anti-spike monoclonal antibody therapy, remdesivir, or both.

Results: A total of 6 patients received a heart transplant from a SARS-CoV-2-positive donor. One heart transplant was complicated by catastrophic secondary graft dysfunction requiring venoarterial extracorporeal membrane oxygenation and retransplant. The remaining 5 patients did well postoperatively and were discharged from the hospital. None of the patients had evidence of COVID-19 infection after surgery.

Conclusion: Heart transplants from SARS-CoV-2 polymerase chain reaction-positive donors are feasible and safe with adequate screening and postexposure prophylaxis.

MeSH terms

  • COVID-19* / diagnosis
  • Heart Transplantation* / adverse effects
  • Humans
  • Pandemics
  • SARS-CoV-2
  • Tissue Donors